Grace Tyson

Research title: Investigating SARS-CoV-2 infection in UK cats: prevalence and significance as a feline pathogen

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021
Number of items: 13.

2024

Kuhn, J. et al. (2024) Investigations on the potential role of free-ranging wildlife as a reservoir of SARS-CoV-2 in Switzerland. Viruses, 16(9), 1407. (doi: 10.3390/v16091407)

Hüttl, J. et al. (2024) Serological and molecular investigation of SARS-CoV-2 in horses and cattle in Switzerland from 2020 to 2022. Viruses, 16(2), 224. (doi: 10.3390/v16020224)

2023

Jones, S. et al. (2023) SARS-CoV-2 in domestic UK cats from Alpha to Omicron: Swab surveillance and case reports. Viruses, 15(8), 1769. (doi: 10.3390/v15081769) (PMID:37632111) (PMCID:PMC10459977)

Tyson, G. B. et al. (2023) Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-Omicron variants. Viruses, 15(8), 1661. (doi: 10.3390/v15081661) (PMID:37632004) (PMCID:PMC10458763)

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Marshall, L., Murcia, P. R. , Willett, B. J. , Weir, W. and Hosie, M. J. (2023) SARS-CoV-2 seroprevalence and cross-variant antibody neutralization in cats, United Kingdom. Emerging Infectious Diseases, 29(6), pp. 1223-1227. (doi: 10.3201/eid2906.221755) (PMID:37141617) (PMCID:PMC10202862)

Kuhlmeier, E. et al. (2023) Risk factor analysis of SARS-CoV-2 infection in animals in COVID-19-affected households. Viruses, 15(3), 731. (doi: 10.3390/v15030731) (PMID:36992440) (PMCID:PMC10051903)

Kuhlmeier, E. et al. (2023) Detection and molecular characterization of the SARS-CoV-2 Delta variant and the specific immune response in companion animals in Switzerland. Viruses, 15(1), 245. (doi: 10.3390/v15010245) (PMID:36680285) (PMCID:PMC9864232)

2022

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Murcia, P. R. , Willett, B. J. , Weir, W. and Hosie, M. J. (2022) Rising SARS-CoV-2 seroprevalence and patterns of cross-variant antibody neutralization in UK domestic cats. bioRxiv, (doi: 10.1101/2022.11.18.517046)

Willett, B. J. et al. (2022) Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5. bioRxiv, (doi: 10.1101/2022.05.25.493397)

Parry, H. et al. (2022) Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 15(1), 3. (doi: 10.1186/s13045-021-01219-7) (PMID:35000597) (PMCID:PMC8743056)

Dowell, A. C. et al. (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 23(1), pp. 40-49. (doi: 10.1038/s41590-021-01089-8) (PMID:34937928) (PMCID:PMC8709786)

2021

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Sziemel, A. M., Hwa, S.-H., Sigal, A., Tyson, G., Logan, N., Willett, B. J. and Durcan, P. J. (2021) Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351. bioRxiv, (doi: 10.1101/2021.04.11.439360)

This list was generated on Tue Nov 19 04:43:22 2024 GMT.
Jump to: Articles
Number of items: 13.

Articles

Kuhn, J. et al. (2024) Investigations on the potential role of free-ranging wildlife as a reservoir of SARS-CoV-2 in Switzerland. Viruses, 16(9), 1407. (doi: 10.3390/v16091407)

Hüttl, J. et al. (2024) Serological and molecular investigation of SARS-CoV-2 in horses and cattle in Switzerland from 2020 to 2022. Viruses, 16(2), 224. (doi: 10.3390/v16020224)

Jones, S. et al. (2023) SARS-CoV-2 in domestic UK cats from Alpha to Omicron: Swab surveillance and case reports. Viruses, 15(8), 1769. (doi: 10.3390/v15081769) (PMID:37632111) (PMCID:PMC10459977)

Tyson, G. B. et al. (2023) Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-Omicron variants. Viruses, 15(8), 1661. (doi: 10.3390/v15081661) (PMID:37632004) (PMCID:PMC10458763)

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Marshall, L., Murcia, P. R. , Willett, B. J. , Weir, W. and Hosie, M. J. (2023) SARS-CoV-2 seroprevalence and cross-variant antibody neutralization in cats, United Kingdom. Emerging Infectious Diseases, 29(6), pp. 1223-1227. (doi: 10.3201/eid2906.221755) (PMID:37141617) (PMCID:PMC10202862)

Kuhlmeier, E. et al. (2023) Risk factor analysis of SARS-CoV-2 infection in animals in COVID-19-affected households. Viruses, 15(3), 731. (doi: 10.3390/v15030731) (PMID:36992440) (PMCID:PMC10051903)

Kuhlmeier, E. et al. (2023) Detection and molecular characterization of the SARS-CoV-2 Delta variant and the specific immune response in companion animals in Switzerland. Viruses, 15(1), 245. (doi: 10.3390/v15010245) (PMID:36680285) (PMCID:PMC9864232)

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Murcia, P. R. , Willett, B. J. , Weir, W. and Hosie, M. J. (2022) Rising SARS-CoV-2 seroprevalence and patterns of cross-variant antibody neutralization in UK domestic cats. bioRxiv, (doi: 10.1101/2022.11.18.517046)

Willett, B. J. et al. (2022) Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5. bioRxiv, (doi: 10.1101/2022.05.25.493397)

Parry, H. et al. (2022) Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 15(1), 3. (doi: 10.1186/s13045-021-01219-7) (PMID:35000597) (PMCID:PMC8743056)

Dowell, A. C. et al. (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 23(1), pp. 40-49. (doi: 10.1038/s41590-021-01089-8) (PMID:34937928) (PMCID:PMC8709786)

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Sziemel, A. M., Hwa, S.-H., Sigal, A., Tyson, G., Logan, N., Willett, B. J. and Durcan, P. J. (2021) Development of highly potent neutralising nanobodies against multiple SARS-CoV-2 variants including the variant of concern B.1.351. bioRxiv, (doi: 10.1101/2021.04.11.439360)

This list was generated on Tue Nov 19 04:43:22 2024 GMT.